|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Subcutaneous injection of TRIM24 iHMECs in nude mice led to growth of intermediate to high-grade tumors in 60-70% of mice.
|
25065590 |
2015 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Collectively, these results identify a role for TRIM24 in breast tumorigenesis through reprogramming of glucose metabolism in HMECs, further supporting TRIM24 as a viable therapeutic target in breast cancer.
|
25065590 |
2015 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tripartite motif-containing 24 (TRIM24), also known as transcription intermediary factor 1-alpha (TIF1α), is a chromatin-associated protein which as been has been implicated in carcinogenesis.
|
25846736 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TRIM24 was originally named transcription intermediary factor 1-alpha (TIF1α), which was associated with cellular proliferation and was an oncogene in tumor development.
|
24409330 |
2014 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Hence, the present study provides evidence that TRIM24 functions as an oncogene in colorectal carcinogenesis.
|
25700357 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression levels of TRIM24 measured in 91 locally advanced HNSCC tumors were measured by immunohistochemistry and correlated with clinical and pathological parameters.
|
23717505 |
2013 |
|
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Altogether, this work is the first study that shows that overexpression of the TRIM24/TIF-1α gene in breast cancer is associated with poor prognosis and worse survival, and it suggests that this transcription coregulator may play a role in mammary carcinogenesis and represent a novel prognostic marker.
|
21435435 |
2011 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Remarkably, Rara haplodeficiency, which suppresses tumorigenesis in Trim24(-/-) mice, prevented IFN/STAT overactivation.
|
21768647 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In a cohort of 19 tamoxifen-resistant breast tumor samples, there was no significant difference in the level of the RIP140 and TIF-1 and corepressor SMRT mRNA compared with tamoxifen-treated tumors (n = 6) or untreated tumors (n = 21).
|
10589759 |
1999 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Although phenotypic overlap exists, anti-Mi2, MDA5, NXP2, TIF1, and SAE antibodies may be correlated with distinct DM subtypes in terms of cutaneous manifestations, systemic involvement, and malignancy risk.
|
31279808 |
2020 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Although phenotypic overlap exists, anti-Mi2, MDA5, NXP2, TIF1, and SAE antibodies may be correlated with distinct DM subtypes in terms of cutaneous manifestations, systemic involvement, and malignancy risk.
|
31279808 |
2020 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Anti-TIF1 and anti-Mi-2 positive patients had an increased risk of malignancy (OR 4.67 and 2.50 respectively), and anti-SRP patients had a greater likelihood of cardiac involvement (OR 4.15).
|
30992170 |
2019 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
All the detected malignancy cases in the anti-TIF1-Ab-positive cohort occurred between 3 years prior to and 2.5 years after DM onset.
|
30535395 |
2019 |
|
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Because of the high relevance of TRIM24 for cancer development and the universal expression of PSMA in CPRC, we investigated the efficacy of human monoclonal PSMA antibody (PSMAb)-based platform for the targeted TRIM24 siRNA delivery and its therapeutic efficacy in CRPC <i>in vivo</i> and <i>in vitro</i>.
|
30867828 |
2019 |
|
Primary malignant neoplasm
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Because of the high relevance of TRIM24 for cancer development and the universal expression of PSMA in CPRC, we investigated the efficacy of human monoclonal PSMA antibody (PSMAb)-based platform for the targeted TRIM24 siRNA delivery and its therapeutic efficacy in CRPC <i>in vivo</i> and <i>in vitro</i>.
|
30867828 |
2019 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
All the detected malignancy cases in the anti-TIF1-Ab-positive cohort occurred between 3 years prior to and 2.5 years after DM onset.
|
30535395 |
2019 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Anti-TIF1 and anti-Mi-2 positive patients had an increased risk of malignancy (OR 4.67 and 2.50 respectively), and anti-SRP patients had a greater likelihood of cardiac involvement (OR 4.15).
|
30992170 |
2019 |
|
Malignant Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.
|
29149307 |
2018 |
|
Primary malignant neoplasm
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.
|
29149307 |
2018 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In this issue of Cancer Cell, Groner et al. show that histone reader and transcription co-regulator TRIM24 occupies a central role in this evolution, nominating inhibitors of TRIM24's bromodomain as a new therapeutic avenue.
|
27300431 |
2016 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
In this issue of Cancer Cell, Groner et al. show that histone reader and transcription co-regulator TRIM24 occupies a central role in this evolution, nominating inhibitors of TRIM24's bromodomain as a new therapeutic avenue.
|
27300431 |
2016 |
|
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
We report here that TRIM24 expression is positively correlated with glioma malignancy and is negatively associated with prognosis of patients with newly diagnosed glioblastoma, which is the most malignant form of gliomas but displays highly heterogeneous clinical outcome.
|
24469053 |
2015 |
|
Primary malignant neoplasm
|
0.070 |
AlteredExpression
|
group |
BEFREE |
We report here that TRIM24 expression is positively correlated with glioma malignancy and is negatively associated with prognosis of patients with newly diagnosed glioblastoma, which is the most malignant form of gliomas but displays highly heterogeneous clinical outcome.
|
24469053 |
2015 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
<b>Conclusion</b>: PSMAb mediated TRIM24 siRNA delivery platform could significantly inhibit cell proliferation, colony-formation, and invasion in PSMA+ CRPC <i>in vitro</i> and suppressed tumor growth and bone loss in PSMA+ CRPC xenograft and bone metastasis model.
|
30867828 |
2019 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
TRIM24 overexpression promoted proliferation, colony formation, and invasion, while TRIM24 depletion inhibited proliferation, colony formation, and invasion.
|
29862279 |
2018 |